This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
OEM Sales is about creating solutions to win customers and making an impact, one deal at a time. In this episode, we have Sean Pitts from GCX corporation to uncover the ins and outs of OEM Sales. Sean discusses the critical qualities that make an exceptional OEM sales representative. If y ou ask, “W hat is OEM sales ?”
Virtual reality is not just a game-changer for medical sales, but a life-changer for all of us. In this episode, Samuel Adeyinka interviews David Howe to explore the world of virtual reality training for medical device sales reps. I love talking about medical devices, software, sales and business. Samuel, I’m doing great.
Sales in the endovascular space is not just about products; it’s about saving lives one catheter at a time. Join us as we explore the pulse of endovascular med device sales and uncover the heart behind the profession. As always, we do our best to bring your guests who are doing things differently in the medical sales space.
Boston is emerging as one of the hottest startup cities in the country, which is great news for sales professionals. These companies are all backed by venture capital and are currently hiring in sales roles. This is by no means an exhaustive list, but here are some great companies to consider for your next sales job. ProfitWell.
According to AbbVie’s internal data, the company collected nearly $10 billion in Humira net revenue from Medicare Part D between 2010 and 2018. AbbVie has obtained or applied for over 250 patents on Humira to block competition from lower-priced biosimilars. Lack of Medicare Negotiation Costing Taxpayers Billions: U.S.
Since 2010, the UK has fallen from 4th to 98th place in overall trade balance in pharmaceuticals, due to fierce global competition, according to the MMIP. Over the same period, similar countries – including Ireland, France, and Germany – have been moving to boosting manufacturing productivity, output, and exports.
The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. ” The action will only be heard if the Competition Appeal Tribunal (CAT) upholds the CMA’s findings against Alliance, it added. .”
Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US. After initially upholding the patent in January, the CAFC subsequently ruled in June that it was not valid, opening the door to low-cost competition to Novartis’ third biggest-selling product.
In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US. Sales in the first half of this year fell 19% to $1.16 Gilenya made revenues of $2.8
The landscape is highly competitive with new prescription medications launching worldwide each year. According to a McKinsey report , a startling 40% of biopharma products fail to meet their sales forecasts within the initial two years, prompting a critical reassessment of strategies for product launches.
Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. Until 2010, no regulatory approval pathway for biosimilars existed in the US and the first biosimilar was only approved in the US in 2015. The biosimilar market in the US may progress differently this time.
It initially targeted seven serotypes, before Pfizer launched an updated version that targeted 13 serotypes in 2010. According to GlobalData, Pharmaceutical Technology’s parent company, Prevnar 13 and Vaxneuvance are forecasted to have global sales of $7.26 VAX-24 has forecasted sales of $21 million in the same year.
The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. These actions allegedly led to the extension of Novartis’ patents.
There was an article that examine the market for generic medicines in the Malaysia, following the introduction of the first generic patent in 2010 and the introduction of generic patent law in 2012. This growth is reflected in improved public health and lower prices for consumers, as well as higher sales of generic medicines.
1 And, on average , the FDA approved 60% more drugs between 2010-2019 than the yearly average over the previous decade. MSLs do not need another system designed for sales reps. The Right Stuff. They want a system that is right for them. The global pool of investigators is growing on average between 3.3-5.6%
Chronology of Events Leading Up to Today Early Days and Meteoric Rise 2010: Fashion Valet was founded by Datin Vivy Yusof and Datuk Fadzaruddin Shah Anuar with a vision of becoming Malaysia’s leading fashion platform. Key Events Leading to the Sale Financial Strain : Fashion Valet struggled to secure additional funding to sustain operations.
PT: How do you think GSK is placed competitively? Important elements within this expectation are the build up of strong contributions from Rotarix, Cervarix and Tykerb, while the outlook for GSK’s important asthma franchise becomes less clear beyond 2010. PD: We believe that GSK has the strongest pipeline in the industry.
The Patient Protection and Affordable Care Act of 2010 has increased access to healthcare services for previously uninsured populations. A buyer persona is a semi-fictional representation of your ideal customer based on sales data and industry research. The more detailed you are, the better.
I have a big playlist of medical sales, medical information, news and innovation. While I was there, I met the hospice world, hospice sales and the ins and outs of hospice care. I remember back in my pharmaceutical sales rep days and I’m talking as far as 2009 or 2010. This is a whole new thing for you?
He was Executive VP and President of Merck’s Global Human Health Division from 2010 to 2019. Prior to becoming President of Global Human Health, he served as President of Merck’s global pharmaceutical business from 2007 to 2010. In this role, he was also a member of Merck’s executive committee.
Pharma giant AstraZeneca also plans to make its supply chain carbon-negative by 2030; to reduce its Scope 1 emissions by 20%, Scope 2 emissions by 95%, and Scope 3 emissions by 25% per $1m of sales by 2025. Access to medication. According to the World Health Organization (WHO), two billion people lack access to essential or basic drugs.
Through our recent report, Scientific innovations for more sustainable growth , we analysed over 300 M&A deals made by the world’s top 30 biopharma companies between 2010–2021. Collaboration across the industry is needed now more than ever before across this complex ecosystem – not least because it’s becoming a competitive landscape.
So there are those tasks as well but At the time when I go back to that sort of 2010 timeframe. Stewart Gandolf Oh, it's a sales thing. The old school way is, you have a sales force, and then you go send in a rep to go see a doctor. by hiring armies of sales, reps. and having sold my company and working on a PhD.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content